Evidence map›Paper›PMID 36559273›Full record

ArticlePharmaceutics2022

Potent Platinum(IV) Prodrugs That Incorporate a Biotin Moiety to Selectively Target Cancer Cells.

Aleen Khoury, Jennette A Sakoff, Jayne Gilbert, Shawan Karan, Christopher P Gordon, Janice R Aldrich-Wright

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Mapping the Landscape of Global Anticancer Organometallics Research: A Systematic Review.Medicinal chemistry (Shariqah (United Arab Emirates)) · 2025
    Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Aleen KhourySchool of Science, Western Sydney University, Locked Bag 1797, Penrith South DC, NSW 2751, Australia.ORCID 0000-0002-7139-9536
Jennette A SakoffCalvary Mater Hospital, Waratah, NSW 2298, Australia.ORCID 0000-0002-7009-5792
Jayne GilbertCalvary Mater Hospital, Waratah, NSW 2298, Australia.ORCID 0000-0001-5034-386X
Shawan KaranTeaching and Research Technical Services, Western Sydney University, Locked Bag 1797, Penrith South DC, NSW 2751, Australia.
Christopher P GordonSchool of Science, Western Sydney University, Locked Bag 1797, Penrith South DC, NSW 2751, Australia.
Janice R Aldrich-WrightSchool of Science, Western Sydney University, Locked Bag 1797, Penrith South DC, NSW 2751, Australia.ORCID 0000-0002-6943-6908
Western Sydney University · AUCalvary Mater Newcastle Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Four platinum(IV) prodrugs incorporating a biotin moiety to selectively target cancer cells were synthesised, characterised, and their biological activity assessed. All complexes exhibited exceptional in vitro cytotoxicity against a panel of cancer cell lines, with [Pt(5,6-dimethyl-1,10-phenanthroline)(1

Indexed as

56MESSbiotincancercellular accumulationcytotoxicitylipophilicityplatinum(IV)prodrugsreceptor targetselectivity

Identifiers

PMID36559273
PMCPMC9853328
OpenAlexW4312113448

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.